Phase II RCT: Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer.
22 Jun, 2022 | 10:49h | UTCSwitch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)